| Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... Cancer discovery 3 (12), 1416-1429, 2013 | 451* | 2013 |
| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ... Scientific reports 4 (1), 1-10, 2014 | 321 | 2014 |
| Axitinib effectively inhibits BCR-ABL1 (T315I) with a distinct binding conformation T Pemovska, E Johnson, M Kontro, GA Repasky, J Chen, P Wells, ... Nature 519 (7541), 102-105, 2015 | 265 | 2015 |
| Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ... Haematologica 105 (3), 708, 2020 | 130 | 2020 |
| Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia M Kontro, H Kuusanmäki, S Eldfors, T Burmeister, EI Andersson, ... Leukemia 28 (8), 1738-1742, 2014 | 126 | 2014 |
| JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML R Karjalainen, T Pemovska, M Popa, M Liu, KK Javarappa, MM Majumder, ... Blood, The Journal of the American Society of Hematology 130 (6), 789-802, 2017 | 124 | 2017 |
| HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ... Leukemia 31 (2), 301-309, 2017 | 90 | 2017 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer discovery 12 (2), 388-401, 2022 | 86 | 2022 |
| Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 134, 570, 2019 | 81 | 2019 |
| Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS … AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, ... Blood 138, 244, 2021 | 80 | 2021 |
| Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic … AM Brunner, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 136, 1-2, 2020 | 76 | 2020 |
| Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia K Kämpjärvi, TM Järvinen, T Heikkinen, AS Ruppert, L Senter, KW Hoag, ... Oncotarget 6 (3), 1884, 2015 | 62 | 2015 |
| Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia JL Kivioja, A Thanasopoulou, A Kumar, M Kontro, B Yadav, MM Majumder, ... Leukemia 33 (6), 1360-1372, 2019 | 55 | 2019 |
| Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ... Leukemia 31 (5), 1187-1195, 2017 | 54 | 2017 |
| Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia S Eldfors, H Kuusanmäki, M Kontro, MM Majumder, A Parsons, H Edgren, ... Leukemia 31 (1), 51-57, 2017 | 52 | 2017 |
| Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms K Kämpjärvi, NH Kim, S Keskitalo, AD Clark, P Von Nandelstadh, ... The Prostate 76 (1), 22-31, 2016 | 44 | 2016 |
| Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML R Karjalainen, M Liu, A Kumar, L He, D Malani, A Parsons, M Kontro, ... Leukemia 33 (10), 2548-2553, 2019 | 35 | 2019 |
| Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing PO Pietarinen, T Pemovska, M Kontro, B Yadav, JP Mpindi, EI Andersson, ... Blood cancer journal 5 (5), e309-e309, 2015 | 35 | 2015 |
| Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ... Blood 141 (13), 1610-1625, 2023 | 34 | 2023 |
| In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL S Laukkanen, T Grönroos, P Pölönen, H Kuusanmäki, J Mehtonen, ... Blood cancer journal 7 (9), e604-e604, 2017 | 32 | 2017 |
